Shares of Merck & Company (NYSE:MRK) advanced to $56.46. The price had gained 0.2% or 0.11 points intraday. The latest trading session witnessed $17.25 million in upticks and $21.56 million in downticks, resulting in net money flow of (-4.32) million. The up/down ratio for the day stood at 0.8. On a weekly scale, the price has seen a change of -0.32%. From the trading data available, it was disclosed that a block trade of negative money flow worth $(-4.15) million occurred during the day. $3.45 million in uptick and $7.61 million in downtick were the highlight of the block transaction which had an up/down ratio of 0.45.
Currently the company Insiders own 0.05% of Merck & Company shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -6.72% . Institutional Investors own 74.23% of Merck & Company shares. During last six month period, the net percent change held by insiders has seen a change of -6.72%. On the companys insider trading activities,The officer (EVP & Chief Info Officer) of Merck & Co., Inc., Golestani Clark sold 39,877 shares at $54.67 on May 19, 2016. The Insider selling transaction had a total value worth of $2,180,076. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Merck & Company (NYSE:MRK) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.24 points or 0.43% at $56.11 with 6,204,834 shares getting traded. Post opening the session at $56.18, the shares hit an intraday low of $56.09 and an intraday high of $56.68 and the price was in this range throughout the day. The company has a market cap of $155,314 million and the number of outstanding shares have been calculated to be 2,768,025,300 shares. The 52-week high of Merck & Company (NYSE:MRK) is $60.07 and the 52-week low is $45.69.
Many analysts have stated their opinion on the company shares. Major Brokerage house, Credit Suisse maintains its ratings on Merck & Company (NYSE:MRK). In the latest research report, Credit Suisse raises the target price from $56 per share to $57 per share. According to the latest information available, the shares are now rated Neutral by the analysts at the agency. The rating by the firm was issued on May 9, 2016.
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.